PE20142043A1 - Enfoque metabolico selectivo para aumentar la biodisponibilidad oral de la fenilefrina y otros bioactivos metabolicos - Google Patents

Enfoque metabolico selectivo para aumentar la biodisponibilidad oral de la fenilefrina y otros bioactivos metabolicos

Info

Publication number
PE20142043A1
PE20142043A1 PE2014000420A PE2014000420A PE20142043A1 PE 20142043 A1 PE20142043 A1 PE 20142043A1 PE 2014000420 A PE2014000420 A PE 2014000420A PE 2014000420 A PE2014000420 A PE 2014000420A PE 20142043 A1 PE20142043 A1 PE 20142043A1
Authority
PE
Peru
Prior art keywords
metabolic
phenylephrin
bioactives
oral bioavailability
selective
Prior art date
Application number
PE2014000420A
Other languages
English (en)
Inventor
Phillip M Gerk
William H Barr
Joseph K Ritter
Original Assignee
Univ Virginia Commonwealth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia Commonwealth filed Critical Univ Virginia Commonwealth
Publication of PE20142043A1 publication Critical patent/PE20142043A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDO A UNA COMPOSICION DE DOSIS ORAL, CARACTERIZADA PORQUE COMPRENDE: UN BIOACTIVO QUE SE SELECCIONA DEL GRUPO DE FENILEFRINA, ALBUTEROL, MAGNOLOL, ENTRE OTROS, Y UNO O MAS INHIBIDORES ENZIMATICOS SELECCIONADOS DEL GRUPO QUE CONSISTE DE QUERCETINA, VAINILLINA, EUGENOL, ENTRE OTROS. TAMBIEN SE REFIERE A UN METODO PARA PROPORCIONAR ORALMENTE DICHA COMPOSICION A UN SUJETO.
PE2014000420A 2011-09-27 2012-09-27 Enfoque metabolico selectivo para aumentar la biodisponibilidad oral de la fenilefrina y otros bioactivos metabolicos PE20142043A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161539530P 2011-09-27 2011-09-27
US201161544396P 2011-10-07 2011-10-07

Publications (1)

Publication Number Publication Date
PE20142043A1 true PE20142043A1 (es) 2014-12-18

Family

ID=47996740

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000420A PE20142043A1 (es) 2011-09-27 2012-09-27 Enfoque metabolico selectivo para aumentar la biodisponibilidad oral de la fenilefrina y otros bioactivos metabolicos

Country Status (15)

Country Link
US (1) US9616033B2 (es)
EP (1) EP2760441A2 (es)
JP (1) JP2014527999A (es)
KR (1) KR20140097135A (es)
AU (1) AU2012316001A1 (es)
BR (1) BR112014007376A2 (es)
CA (1) CA2849473A1 (es)
CL (1) CL2014000747A1 (es)
CO (1) CO6970592A2 (es)
IL (1) IL231635A0 (es)
MX (1) MX2014003606A (es)
PE (1) PE20142043A1 (es)
RU (1) RU2014116639A (es)
SG (1) SG11201400897UA (es)
WO (1) WO2013049365A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014168925A1 (en) * 2013-04-08 2014-10-16 Virginia Commonwealth University Compositions to alleviate presystemic metabolism of opioids
SI3157506T1 (sl) 2014-06-20 2021-01-29 Hermes Arzneimittel Gmbh Oralni farmacevtski sestavek z zamaskiranim okusom
BR112017001732A2 (pt) * 2014-07-30 2017-11-21 Merck Patent Gmbh composição diretamente compressível contendo celulose microcristalina
KR101621426B1 (ko) 2014-08-20 2016-05-16 선문대학교 산학협력단 신규한 알파-망고스틴 글리코시드 유도체 및 이의 제조방법
FR3027228B1 (fr) * 2014-10-20 2016-12-09 Valbiotis Composition comprenant un melange d'extraits vegetaux et utilisation pour agir sur le metabolisme glucidique et/ou lipidique
US9907786B2 (en) 2014-10-21 2018-03-06 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US10092550B2 (en) 2014-10-21 2018-10-09 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
US20160106721A1 (en) 2014-10-21 2016-04-21 Life Plus, LLC Human therapeutic agents
US10123991B2 (en) 2015-05-15 2018-11-13 Global Biolife Inc. Electrophilically enhanced phenolic compounds for treating inflammatory related diseases and disorders
CN107515307A (zh) * 2017-10-13 2017-12-26 基蛋生物科技股份有限公司 一种干式免疫心血管八指标检测试纸条
WO2020049588A1 (en) * 2018-09-05 2020-03-12 THAKKAR Hetal Paresh Technology for enhancing bioavalaibility of selective estrogen receptor modulator (serm)
CN113671093A (zh) * 2020-05-13 2021-11-19 上海大学 快速检测人体尿液中对羟基苯甲酸类物质的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4493827A (en) 1983-11-14 1985-01-15 Ronald Valle Method of inducing sleep
CN1122103A (zh) * 1993-04-30 1996-05-08 普罗克特和甘保尔公司 包衣药剂组合物
US6180666B1 (en) 1997-09-05 2001-01-30 Anmax, Inc. Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds
US6759062B2 (en) 2000-02-23 2004-07-06 Bioselect Innovations, Inc. Composition and method for treating the effects of diseases and maladies
CA2424021A1 (en) 2000-09-29 2002-04-04 Board Of Trustees Operating Michigan State University Catecholamine compositions and uses thereof
WO2003055494A1 (en) 2001-12-21 2003-07-10 Avmax, Inc. Use of ugt inhibitors to increase bioavailability
US20040214215A1 (en) * 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20070160688A1 (en) * 2006-01-10 2007-07-12 Eric Marchewitz Use of flavonoids to increase blood serum levels of dehydroepiandrosterone
US20070160689A1 (en) * 2006-01-12 2007-07-12 Everett Laboratories, Inc. Compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
ES2391585T3 (es) * 2006-06-01 2012-11-28 Msd Consumer Care, Inc. Formulación farmacéutica de liberación sostenida que comprende fenilefrina
US20080069874A1 (en) 2006-09-15 2008-03-20 Auriga Laboratories, Inc. Kits for Prevention and Treatment of Rhinitis
KR101677126B1 (ko) * 2008-05-20 2016-11-22 노이로제스엑스, 인코포레이티드 탄산염 프로드러그 및 그것의 사용 방법

Also Published As

Publication number Publication date
WO2013049365A2 (en) 2013-04-04
US20140221426A1 (en) 2014-08-07
BR112014007376A2 (pt) 2017-04-04
US9616033B2 (en) 2017-04-11
JP2014527999A (ja) 2014-10-23
RU2014116639A (ru) 2015-11-10
WO2013049365A3 (en) 2013-05-30
AU2012316001A1 (en) 2014-04-10
SG11201400897UA (en) 2014-04-28
EP2760441A2 (en) 2014-08-06
CO6970592A2 (es) 2014-06-13
IL231635A0 (en) 2014-05-28
CL2014000747A1 (es) 2015-02-27
CA2849473A1 (en) 2013-04-04
MX2014003606A (es) 2015-01-16
KR20140097135A (ko) 2014-08-06

Similar Documents

Publication Publication Date Title
PE20142043A1 (es) Enfoque metabolico selectivo para aumentar la biodisponibilidad oral de la fenilefrina y otros bioactivos metabolicos
NI201600058A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
UY33370A (es) Composiciones farmacéuticas comprendiendo un fármaco inhibidor de la DPP4 y de la pioglitazona, procedimientos de preparación y utilización
CO6761389A2 (es) Inhibidores de nampt y rock
CL2014000245A1 (es) Compuestos derivados de heterociclos nitrogenados, inhibidores de replicacion de los virus de influenza; metodo de preparacion; composicionn farmaceutica; metodo para inhibir la replicacion del virus de la influenza en una muestra biológica o un paciente.
ECSP15013227A (es) Formulaciones acuosas estables de adalimumab
CR20140321A (es) Sistema de administracion transdermica que contiene buprenofina
DOP2014000253A (es) Inhibidores del nampt
CR20150647A (es) Sistema de liberación transdérmica
UY35210A (es) Inhibidores de autotaxina
CL2014000183A1 (es) Formulación farmacéutica que contienen anticuerpos anti-pcsk9; metodo para preparar dicha formulación.
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
CL2015000744A1 (es) Combinación de regorafenib y ácido acetilsalicílico para el tratamiento del cáncer.
UY32809A (es) Compuestos y composiciones como inhibidores de cinasa s y k
IT1400982B1 (it) Collirio osmotico trans-epiteliale per la cura del cheratocono.
PE20151005A1 (es) Composicion farmaceutica recubierta que contiene regorafenib
DOP2016000253A (es) Nuevos compuestos
UY32776A (es) Compuestos de imidazopirazinas sustituidas para el tratamiento de enfermedades parasitarias,composiciones farmacéuticas que los contienen y aplicación.
UY31788A (es) Formulación farmacéutica sólida con liberación retardada
CL2015003468A1 (es) Composicion solida para administracion oral conteniendo acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d.
CR20150266A (es) Formulaciones de liberación modificada para oprozomib
GT201700280A (es) Formulación sólida oral que contiene irinotecán y método de preparación de la misma
CU24163B1 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
AR091739A1 (es) Composiciones y metodos para reducir el riesgo cardiometabolico

Legal Events

Date Code Title Description
FA Abandonment or withdrawal